+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Brain Tumor Diagnosis & Treatment Market by Treatment Type, Diagnosis Type, End User, Tumor Type - Global Forecast to 2030- Product Image
Brain Tumor Diagnosis & Treatment Market by Treatment Type, Diagnosis Type, End User, Tumor Type - Global Forecast to 2030- Product Image
Sale

Brain Tumor Diagnosis & Treatment Market by Treatment Type, Diagnosis Type, End User, Tumor Type - Global Forecast to 2030

  • PDF Icon

    Report

  • 181 Pages
  • May 2025
  • Region: Global
  • 360iResearch™
  • ID: 6011113
UP TO OFF until Jan 01st 2026
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.
The Brain Tumor Diagnosis & Treatment Market grew from USD 1.80 billion in 2024 to USD 1.93 billion in 2025. It is expected to continue growing at a CAGR of 6.87%, reaching USD 2.69 billion by 2030.

Redefining the Horizon of Brain Tumor Care

Brain tumors represent one of the most formidable challenges in oncology, demanding a confluence of cutting-edge diagnostic technologies and advanced therapeutic strategies. As diagnostic modalities evolve from traditional imaging and histopathology toward molecular assays and precision medicine, the clinical pathway is being reimagined at every juncture. Simultaneously, the treatment landscape is expanding beyond conventional surgery, chemotherapy, and radiotherapy to include targeted agents, immunotherapies, and novel combination regimens.

In this dynamic environment, decision-makers require a robust synthesis of emerging trends, regulatory influences, and evolving patient demographics. This executive summary offers a strategic overview of pivotal developments in brain tumor diagnosis and treatment, emphasizing shifts in market drivers, segmentation nuances, regional performance, and leading players. By contextualizing the cumulative impact of policy measures such as United States tariffs, this report equips stakeholders with the clarity needed to anticipate supply chain fluctuations and cost pressures.

Revolutionary Shifts Reshaping Diagnosis and Treatment

The past few years have witnessed an unprecedented pace of innovation that is reshaping how clinicians detect and combat brain tumors. Artificial intelligence-driven image analysis is now providing radiologists with enhanced lesion characterization, while liquid biopsy techniques are emerging as minimally invasive tools for real-time tumor monitoring. On the therapeutic front, advances in immuno-oncology have unlocked new avenues for harnessing the patient’s own immune system, with CAR T-cell therapies and checkpoint inhibitors demonstrating promise in select glioma subtypes.

Moreover, precision medicine initiatives are driving the development of targeted therapies against specific genetic mutations, such as IDH1/IDH2 inhibitors and agents aimed at the EGFR pathway. These breakthroughs are not only improving survival outcomes but also reshaping the competitive landscape, compelling traditional pharmaceutical and medtech companies to form strategic alliances with biotech innovators and academic research centers. The synergy between diagnostics and treatment is becoming more pronounced, as companion diagnostics evolve in tandem with therapeutic assets to ensure personalized care pathways.

Assessing the Ripple Effects of U.S. Tariffs 2025

The introduction of new tariffs on imported diagnostic equipment and therapeutic agents has introduced layer of complexity for manufacturers and healthcare providers alike. Increased duties on advanced imaging machinery and critical reagents have exerted upward pressure on capital expenditures and per-procedure costs, prompting some institutions to reevaluate procurement strategies. Simultaneously, higher tariffs on active pharmaceutical ingredients have influenced supply chain realignments, with a growing number of suppliers seeking alternative manufacturing hubs outside of the United States.

Despite these challenges, market participants have responded with adaptive measures that include localized manufacturing partnerships, long-term supplier contracts, and tiered pricing agreements. These initiatives are helping to stabilize costs and ensure continuity of care for patients. However, the lingering uncertainty around potential adjustments in trade policy underscores the importance of ongoing scenario analysis. Stakeholders who proactively assess tariff impacts and diversify sourcing arrangements will be better positioned to mitigate risk and sustain innovation in brain tumor diagnosis and treatment.

Decoding the Multidimensional Segmentation Landscape

The complexity of the brain tumor diagnosis and treatment market becomes clearer when examined through the lens of multiple segmentation dimensions. Based on treatment type, the landscape encompasses chemotherapy regimens-spanning temozolomide, nitrosoureas, and combination therapies-alongside a robust immunotherapy portfolio that includes checkpoint inhibitors, vaccines, and CAR T-cell approaches. Radiotherapy offerings range from external beam and stereotactic radiosurgery to brachytherapy, while targeted treatments focus on molecular inhibitors such as bevacizumab, mTOR modulators, and tyrosine kinase agents.

When viewed according to diagnosis type, this market integrates traditional biopsy techniques-both open and stereotactic-with advanced imaging modalities including computed tomography, magnetic resonance imaging, positron emission tomography, and ultrasound. Molecular diagnostics further enrich the toolkit with gene expression profiling, next-generation sequencing, and PCR-based assays. From the vantage of end users, the ecosystem extends across diagnostic centers, hospitals, specialty clinics, and research institutes, each with distinct adoption curves and investment capacities. Tumor type segmentation highlights the heterogeneity of clinical need, with entities such as glioma subtypes-astrocytoma, glioblastoma, oligodendroglioma-alongside medulloblastoma, meningioma, craniopharyngioma, and pituitary adenomas driving tailored research and development agendas.

Unearthing Regional Dynamics Across Global Markets

Regional analysis unveils a tapestry of growth trajectories shaped by healthcare infrastructure, regulatory environments, and socio-economic drivers. In the Americas, investment in state-of-the-art diagnostic centers and robust reimbursement frameworks have accelerated adoption of sophisticated imaging and molecular testing, while North America remains a hotbed for clinical trials and therapeutic innovation. Conversely, Latin American markets are characterized by selective access models and an increasing focus on capacity building in tertiary care facilities.

In Europe, Middle East & Africa, variabilities in public funding and market authorization processes create a mosaic of opportunity and complexity. Western Europe’s centralized reimbursement pathways facilitate rapid adoption of novel therapies, whereas EMEA regions with emerging economies are witnessing growing public-private partnerships aimed at expanding diagnostic coverage. The Asia-Pacific region is experiencing the fastest uptake in digital pathology and telemedicine, driven by escalating patient demand, government-backed healthcare modernization programs, and strategic collaborations between local and international firms. Each geography’s unique dynamics underscore the need for tailored market entry strategies and agile stakeholder engagement.

Spotlight on Industry Leaders Driving Innovation

The competitive arena in brain tumor diagnosis and treatment is defined by a blend of established pharmaceutical giants, innovative biotech firms, and leading medical device manufacturers. Companies with vertically integrated capabilities-from diagnostic assay development to therapeutic pipeline management-are leveraging strategic acquisitions and licensing partnerships to expand their portfolios. Meanwhile, emerging players are carving niches by focusing on high-precision molecular diagnostics and next-generation immuno-oncology platforms.

Collaborations between academia and industry have become increasingly prevalent, accelerating the translation of laboratory discoveries into clinical applications. Key alliances are being forged around companion diagnostic tests for targeted therapies, as well as in co-development of advanced radiopharmaceuticals. Competitive differentiation now hinges on a company’s ability to demonstrate clinical efficacy, regulatory agility, and reimbursement viability. Intellectual property positioning and a demonstrated track record in strategic alliance execution are emerging as pivotal determinants of long-term success.

Strategic Imperatives for Navigating Future Challenges

To thrive in the rapidly evolving brain tumor landscape, industry leaders must embrace a multi-pronged strategy. Prioritizing investment in precision diagnostics and companion assays will enable a seamless transition from early detection to personalized treatment regimens. Supply chain diversification-through regional manufacturing hubs and multi-source procurement agreements-will mitigate tariff-related and geopolitical risks. Strategic collaborations with research institutes and technology partners can accelerate pipeline development while sharing investment burdens.

Moreover, engaging with payers and policymakers early in the product lifecycle will facilitate smoother market access and reimbursement alignment. Leaders should also deploy advanced data analytics and real-world evidence generation to demonstrate value and optimize clinical pathways. By integrating these initiatives into a cohesive strategic roadmap, organizations can not only navigate near-term challenges but also establish a foundation for sustained innovation and competitive advantage.

Rigor and Precision Underpinning the Research Approach

This report’s findings are underpinned by a rigorous methodology combining secondary research, primary interviews, and data validation to ensure credibility and depth. The secondary research phase involved comprehensive review of peer-reviewed journals, industry white papers, regulatory filings, and company annual reports. Primary interviews were conducted with key opinion leaders, including neuro-oncologists, diagnostic radiologists, biotech executives, and procurement specialists, providing firsthand insights into clinical adoption trends and market dynamics.

Data triangulation techniques were applied to reconcile differing sources, while an iterative peer review process ensured consistency and minimized bias. All market metrics and qualitative assessments were cross-checked against multiple independent data points. Regional market sizing and segmentation insights reflect the latest regulatory approvals, reimbursement policies, and clinical guideline updates, delivering a robust framework for strategic decision-making.

Synthesizing Insights for Informed Decision-Making

In synthesizing the intricate variables shaping the brain tumor diagnosis and treatment market, several thematic conclusions emerge. First, the convergence of advanced diagnostics and targeted therapies is redefining clinical pathways, ushering in a new era of personalized medicine. Second, policy measures such as the U.S. tariffs have introduced cost considerations that require proactive supply chain strategies and localized manufacturing solutions. Third, regional market heterogeneity demands agile, localized approaches to market entry, reimbursement negotiation, and stakeholder engagement.

Furthermore, the competitive landscape is increasingly collaboration-driven, with alliances between established companies and nimble innovators accelerating time to market. Companies that align their portfolios around high-value, precision-focused assets and engage payers early will set the benchmark for sustainable growth. These insights coalesce to form a strategic blueprint for stakeholders aiming to capture value, manage risk, and catalyze breakthroughs in brain tumor care.

Market Segmentation & Coverage

This research report categorizes to forecast the revenues and analyze trends in each of the following sub-segmentations:
  • Treatment Type
    • Chemotherapy
      • Combination Therapies
      • Nitrosoureas
      • Temozolomide
    • Immunotherapy
      • Car T-Cell Therapy
      • Checkpoint Inhibitors
      • Vaccines
    • Radiotherapy
      • Brachytherapy
      • External Beam Radiotherapy
      • Stereotactic Radiosurgery
    • Surgery
    • Targeted Therapy
      • Bevacizumab
      • Mtor Inhibitors
      • Tyrosine Kinase Inhibitors
  • Diagnosis Type
    • Biopsy
      • Open Biopsy
      • Stereotactic Biopsy
    • Imaging
      • Computed Tomography
      • Magnetic Resonance Imaging
      • Positron Emission Tomography
      • Ultrasound
    • Molecular Diagnostics
      • Gene Expression Profiling
      • Next Generation Sequencing
      • Pcr-Based Assays
  • End User
    • Diagnostic Centers
    • Hospitals
    • Research Institutes
    • Specialty Clinics
  • Tumor Type
    • Glioma
      • Astrocytoma
      • Glioblastoma
      • Oligodendroglioma
    • Medulloblastoma
    • Meningioma
    • Pituitary Tumor
      • Craniopharyngioma
      • Pituitary Adenoma
This research report categorizes to forecast the revenues and analyze trends in each of the following sub-regions:
  • Americas
    • United States
      • California
      • Texas
      • New York
      • Florida
      • Illinois
      • Pennsylvania
      • Ohio
    • Canada
    • Mexico
    • Brazil
    • Argentina
  • Europe, Middle East & Africa
    • United Kingdom
    • Germany
    • France
    • Russia
    • Italy
    • Spain
    • United Arab Emirates
    • Saudi Arabia
    • South Africa
    • Denmark
    • Netherlands
    • Qatar
    • Finland
    • Sweden
    • Nigeria
    • Egypt
    • Turkey
    • Israel
    • Norway
    • Poland
    • Switzerland
  • Asia-Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
    • Indonesia
    • Thailand
    • Philippines
    • Malaysia
    • Singapore
    • Vietnam
    • Taiwan
This research report categorizes to delves into recent significant developments and analyze trends in each of the following companies:
  • Siemens Healthineers AG
  • GE Healthcare LLC
  • Koninklijke Philips N.V.
  • Elekta AB
  • Varian Medical Systems, Inc.
  • Accuray Incorporated
  • Roche Holding AG
  • Novartis AG
  • Merck & Co., Inc.
  • Novocure Limited

 

Additional Product Information:

  • Purchase of this report includes 1 year online access with quarterly updates.
  • This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Market Sizing & Forecasting
5. Market Dynamics
6. Market Insights
6.1. Porter’s Five Forces Analysis
6.2. PESTLE Analysis
7. Cumulative Impact of United States Tariffs 2025
8. Brain Tumor Diagnosis & Treatment Market, by Treatment Type
8.1. Introduction
8.2. Chemotherapy
8.2.1. Combination Therapies
8.2.2. Nitrosoureas
8.2.3. Temozolomide
8.3. Immunotherapy
8.3.1. Car T-Cell Therapy
8.3.2. Checkpoint Inhibitors
8.3.3. Vaccines
8.4. Radiotherapy
8.4.1. Brachytherapy
8.4.2. External Beam Radiotherapy
8.4.3. Stereotactic Radiosurgery
8.5. Surgery
8.6. Targeted Therapy
8.6.1. Bevacizumab
8.6.2. Mtor Inhibitors
8.6.3. Tyrosine Kinase Inhibitors
9. Brain Tumor Diagnosis & Treatment Market, by Diagnosis Type
9.1. Introduction
9.2. Biopsy
9.2.1. Open Biopsy
9.2.2. Stereotactic Biopsy
9.3. Imaging
9.3.1. Computed Tomography
9.3.2. Magnetic Resonance Imaging
9.3.3. Positron Emission Tomography
9.3.4. Ultrasound
9.4. Molecular Diagnostics
9.4.1. Gene Expression Profiling
9.4.2. Next Generation Sequencing
9.4.3. Pcr-Based Assays
10. Brain Tumor Diagnosis & Treatment Market, by End User
10.1. Introduction
10.2. Diagnostic Centers
10.3. Hospitals
10.4. Research Institutes
10.5. Specialty Clinics
11. Brain Tumor Diagnosis & Treatment Market, by Tumor Type
11.1. Introduction
11.2. Glioma
11.2.1. Astrocytoma
11.2.2. Glioblastoma
11.2.3. Oligodendroglioma
11.3. Medulloblastoma
11.4. Meningioma
11.5. Pituitary Tumor
11.5.1. Craniopharyngioma
11.5.2. Pituitary Adenoma
12. Americas Brain Tumor Diagnosis & Treatment Market
12.1. Introduction
12.2. United States
12.3. Canada
12.4. Mexico
12.5. Brazil
12.6. Argentina
13. Europe, Middle East & Africa Brain Tumor Diagnosis & Treatment Market
13.1. Introduction
13.2. United Kingdom
13.3. Germany
13.4. France
13.5. Russia
13.6. Italy
13.7. Spain
13.8. United Arab Emirates
13.9. Saudi Arabia
13.10. South Africa
13.11. Denmark
13.12. Netherlands
13.13. Qatar
13.14. Finland
13.15. Sweden
13.16. Nigeria
13.17. Egypt
13.18. Turkey
13.19. Israel
13.20. Norway
13.21. Poland
13.22. Switzerland
14. Asia-Pacific Brain Tumor Diagnosis & Treatment Market
14.1. Introduction
14.2. China
14.3. India
14.4. Japan
14.5. Australia
14.6. South Korea
14.7. Indonesia
14.8. Thailand
14.9. Philippines
14.10. Malaysia
14.11. Singapore
14.12. Vietnam
14.13. Taiwan
15. Competitive Landscape
15.1. Market Share Analysis, 2024
15.2. FPNV Positioning Matrix, 2024
15.3. Competitive Analysis
15.3.1. Siemens Healthineers AG
15.3.2. GE Healthcare LLC
15.3.3. Koninklijke Philips N.V.
15.3.4. Elekta AB
15.3.5. Varian Medical Systems, Inc.
15.3.6. Accuray Incorporated
15.3.7. Roche Holding AG
15.3.8. Novartis AG
15.3.9. Merck & Co., Inc.
15.3.10. Novocure Limited
16. ResearchAI
17. ResearchStatistics
18. ResearchContacts
19. ResearchArticles
20. Appendix
List of Figures
FIGURE 1. BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET MULTI-CURRENCY
FIGURE 2. BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET MULTI-LANGUAGE
FIGURE 3. BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET RESEARCH PROCESS
FIGURE 4. GLOBAL BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 5. GLOBAL BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 6. GLOBAL BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 7. GLOBAL BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2024 VS 2030 (%)
FIGURE 8. GLOBAL BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 9. GLOBAL BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY DIAGNOSIS TYPE, 2024 VS 2030 (%)
FIGURE 10. GLOBAL BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY DIAGNOSIS TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 11. GLOBAL BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY END USER, 2024 VS 2030 (%)
FIGURE 12. GLOBAL BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY END USER, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 13. GLOBAL BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY TUMOR TYPE, 2024 VS 2030 (%)
FIGURE 14. GLOBAL BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY TUMOR TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 15. AMERICAS BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 16. AMERICAS BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 17. UNITED STATES BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY STATE, 2024 VS 2030 (%)
FIGURE 18. UNITED STATES BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 19. EUROPE, MIDDLE EAST & AFRICA BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 20. EUROPE, MIDDLE EAST & AFRICA BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 21. ASIA-PACIFIC BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 22. ASIA-PACIFIC BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 23. BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SHARE, BY KEY PLAYER, 2024
FIGURE 24. BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET, FPNV POSITIONING MATRIX, 2024
List of Tables
TABLE 1. BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
TABLE 3. GLOBAL BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 4. GLOBAL BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
TABLE 5. GLOBAL BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 6. GLOBAL BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 7. GLOBAL BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY CHEMOTHERAPY, BY REGION, 2018-2030 (USD MILLION)
TABLE 8. GLOBAL BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY COMBINATION THERAPIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 9. GLOBAL BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY NITROSOUREAS, BY REGION, 2018-2030 (USD MILLION)
TABLE 10. GLOBAL BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY TEMOZOLOMIDE, BY REGION, 2018-2030 (USD MILLION)
TABLE 11. GLOBAL BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY CHEMOTHERAPY, 2018-2030 (USD MILLION)
TABLE 12. GLOBAL BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY IMMUNOTHERAPY, BY REGION, 2018-2030 (USD MILLION)
TABLE 13. GLOBAL BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY CAR T-CELL THERAPY, BY REGION, 2018-2030 (USD MILLION)
TABLE 14. GLOBAL BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY CHECKPOINT INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
TABLE 15. GLOBAL BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY VACCINES, BY REGION, 2018-2030 (USD MILLION)
TABLE 16. GLOBAL BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY IMMUNOTHERAPY, 2018-2030 (USD MILLION)
TABLE 17. GLOBAL BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY RADIOTHERAPY, BY REGION, 2018-2030 (USD MILLION)
TABLE 18. GLOBAL BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY BRACHYTHERAPY, BY REGION, 2018-2030 (USD MILLION)
TABLE 19. GLOBAL BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY EXTERNAL BEAM RADIOTHERAPY, BY REGION, 2018-2030 (USD MILLION)
TABLE 20. GLOBAL BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY STEREOTACTIC RADIOSURGERY, BY REGION, 2018-2030 (USD MILLION)
TABLE 21. GLOBAL BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY RADIOTHERAPY, 2018-2030 (USD MILLION)
TABLE 22. GLOBAL BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY SURGERY, BY REGION, 2018-2030 (USD MILLION)
TABLE 23. GLOBAL BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY TARGETED THERAPY, BY REGION, 2018-2030 (USD MILLION)
TABLE 24. GLOBAL BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY BEVACIZUMAB, BY REGION, 2018-2030 (USD MILLION)
TABLE 25. GLOBAL BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY MTOR INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
TABLE 26. GLOBAL BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY TYROSINE KINASE INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
TABLE 27. GLOBAL BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
TABLE 28. GLOBAL BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY DIAGNOSIS TYPE, 2018-2030 (USD MILLION)
TABLE 29. GLOBAL BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY BIOPSY, BY REGION, 2018-2030 (USD MILLION)
TABLE 30. GLOBAL BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY OPEN BIOPSY, BY REGION, 2018-2030 (USD MILLION)
TABLE 31. GLOBAL BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY STEREOTACTIC BIOPSY, BY REGION, 2018-2030 (USD MILLION)
TABLE 32. GLOBAL BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY BIOPSY, 2018-2030 (USD MILLION)
TABLE 33. GLOBAL BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY IMAGING, BY REGION, 2018-2030 (USD MILLION)
TABLE 34. GLOBAL BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY COMPUTED TOMOGRAPHY, BY REGION, 2018-2030 (USD MILLION)
TABLE 35. GLOBAL BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY MAGNETIC RESONANCE IMAGING, BY REGION, 2018-2030 (USD MILLION)
TABLE 36. GLOBAL BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY POSITRON EMISSION TOMOGRAPHY, BY REGION, 2018-2030 (USD MILLION)
TABLE 37. GLOBAL BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY ULTRASOUND, BY REGION, 2018-2030 (USD MILLION)
TABLE 38. GLOBAL BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY IMAGING, 2018-2030 (USD MILLION)
TABLE 39. GLOBAL BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY MOLECULAR DIAGNOSTICS, BY REGION, 2018-2030 (USD MILLION)
TABLE 40. GLOBAL BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY GENE EXPRESSION PROFILING, BY REGION, 2018-2030 (USD MILLION)
TABLE 41. GLOBAL BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY NEXT GENERATION SEQUENCING, BY REGION, 2018-2030 (USD MILLION)
TABLE 42. GLOBAL BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY PCR-BASED ASSAYS, BY REGION, 2018-2030 (USD MILLION)
TABLE 43. GLOBAL BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2030 (USD MILLION)
TABLE 44. GLOBAL BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 45. GLOBAL BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY DIAGNOSTIC CENTERS, BY REGION, 2018-2030 (USD MILLION)
TABLE 46. GLOBAL BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
TABLE 47. GLOBAL BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY RESEARCH INSTITUTES, BY REGION, 2018-2030 (USD MILLION)
TABLE 48. GLOBAL BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2018-2030 (USD MILLION)
TABLE 49. GLOBAL BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY TUMOR TYPE, 2018-2030 (USD MILLION)
TABLE 50. GLOBAL BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY GLIOMA, BY REGION, 2018-2030 (USD MILLION)
TABLE 51. GLOBAL BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY ASTROCYTOMA, BY REGION, 2018-2030 (USD MILLION)
TABLE 52. GLOBAL BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY GLIOBLASTOMA, BY REGION, 2018-2030 (USD MILLION)
TABLE 53. GLOBAL BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY OLIGODENDROGLIOMA, BY REGION, 2018-2030 (USD MILLION)
TABLE 54. GLOBAL BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY GLIOMA, 2018-2030 (USD MILLION)
TABLE 55. GLOBAL BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY MEDULLOBLASTOMA, BY REGION, 2018-2030 (USD MILLION)
TABLE 56. GLOBAL BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY MENINGIOMA, BY REGION, 2018-2030 (USD MILLION)
TABLE 57. GLOBAL BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY PITUITARY TUMOR, BY REGION, 2018-2030 (USD MILLION)
TABLE 58. GLOBAL BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY CRANIOPHARYNGIOMA, BY REGION, 2018-2030 (USD MILLION)
TABLE 59. GLOBAL BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY PITUITARY ADENOMA, BY REGION, 2018-2030 (USD MILLION)
TABLE 60. GLOBAL BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY PITUITARY TUMOR, 2018-2030 (USD MILLION)
TABLE 61. AMERICAS BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 62. AMERICAS BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY CHEMOTHERAPY, 2018-2030 (USD MILLION)
TABLE 63. AMERICAS BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY IMMUNOTHERAPY, 2018-2030 (USD MILLION)
TABLE 64. AMERICAS BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY RADIOTHERAPY, 2018-2030 (USD MILLION)
TABLE 65. AMERICAS BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
TABLE 66. AMERICAS BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY DIAGNOSIS TYPE, 2018-2030 (USD MILLION)
TABLE 67. AMERICAS BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY BIOPSY, 2018-2030 (USD MILLION)
TABLE 68. AMERICAS BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY IMAGING, 2018-2030 (USD MILLION)
TABLE 69. AMERICAS BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2030 (USD MILLION)
TABLE 70. AMERICAS BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 71. AMERICAS BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY TUMOR TYPE, 2018-2030 (USD MILLION)
TABLE 72. AMERICAS BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY GLIOMA, 2018-2030 (USD MILLION)
TABLE 73. AMERICAS BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY PITUITARY TUMOR, 2018-2030 (USD MILLION)
TABLE 74. AMERICAS BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 75. UNITED STATES BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 76. UNITED STATES BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY CHEMOTHERAPY, 2018-2030 (USD MILLION)
TABLE 77. UNITED STATES BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY IMMUNOTHERAPY, 2018-2030 (USD MILLION)
TABLE 78. UNITED STATES BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY RADIOTHERAPY, 2018-2030 (USD MILLION)
TABLE 79. UNITED STATES BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
TABLE 80. UNITED STATES BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY DIAGNOSIS TYPE, 2018-2030 (USD MILLION)
TABLE 81. UNITED STATES BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY BIOPSY, 2018-2030 (USD MILLION)
TABLE 82. UNITED STATES BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY IMAGING, 2018-2030 (USD MILLION)
TABLE 83. UNITED STATES BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2030 (USD MILLION)
TABLE 84. UNITED STATES BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 85. UNITED STATES BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY TUMOR TYPE, 2018-2030 (USD MILLION)
TABLE 86. UNITED STATES BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY GLIOMA, 2018-2030 (USD MILLION)
TABLE 87. UNITED STATES BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY PITUITARY TUMOR, 2018-2030 (USD MILLION)
TABLE 88. UNITED STATES BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
TABLE 89. CANADA BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 90. CANADA BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY CHEMOTHERAPY, 2018-2030 (USD MILLION)
TABLE 91. CANADA BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY IMMUNOTHERAPY, 2018-2030 (USD MILLION)
TABLE 92. CANADA BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY RADIOTHERAPY, 2018-2030 (USD MILLION)
TABLE 93. CANADA BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
TABLE 94. CANADA BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY DIAGNOSIS TYPE, 2018-2030 (USD MILLION)
TABLE 95. CANADA BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY BIOPSY, 2018-2030 (USD MILLION)
TABLE 96. CANADA BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY IMAGING, 2018-2030 (USD MILLION)
TABLE 97. CANADA BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2030 (USD MILLION)
TABLE 98. CANADA BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 99. CANADA BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY TUMOR TYPE, 2018-2030 (USD MILLION)
TABLE 100. CANADA BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY GLIOMA, 2018-2030 (USD MILLION)
TABLE 101. CANADA BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY PITUITARY TUMOR, 2018-2030 (USD MILLION)
TABLE 102. MEXICO BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 103. MEXICO BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY CHEMOTHERAPY, 2018-2030 (USD MILLION)
TABLE 104. MEXICO BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY IMMUNOTHERAPY, 2018-2030 (USD MILLION)
TABLE 105. MEXICO BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY RADIOTHERAPY, 2018-2030 (USD MILLION)
TABLE 106. MEXICO BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
TABLE 107. MEXICO BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY DIAGNOSIS TYPE, 2018-2030 (USD MILLION)
TABLE 108. MEXICO BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY BIOPSY, 2018-2030 (USD MILLION)
TABLE 109. MEXICO BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY IMAGING, 2018-2030 (USD MILLION)
TABLE 110. MEXICO BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2030 (USD MILLION)
TABLE 111. MEXICO BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 112. MEXICO BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY TUMOR TYPE, 2018-2030 (USD MILLION)
TABLE 113. MEXICO BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY GLIOMA, 2018-2030 (USD MILLION)
TABLE 114. MEXICO BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY PITUITARY TUMOR, 2018-2030 (USD MILLION)
TABLE 115. BRAZIL BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 116. BRAZIL BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY CHEMOTHERAPY, 2018-2030 (USD MILLION)
TABLE 117. BRAZIL BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY IMMUNOTHERAPY, 2018-2030 (USD MILLION)
TABLE 118. BRAZIL BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY RADIOTHERAPY, 2018-2030 (USD MILLION)
TABLE 119. BRAZIL BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
TABLE 120. BRAZIL BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY DIAGNOSIS TYPE, 2018-2030 (USD MILLION)
TABLE 121. BRAZIL BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY BIOPSY, 2018-2030 (USD MILLION)
TABLE 122. BRAZIL BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY IMAGING, 2018-2030 (USD MILLION)
TABLE 123. BRAZIL BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2030 (USD MILLION)
TABLE 124. BRAZIL BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 125. BRAZIL BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY TUMOR TYPE, 2018-2030 (USD MILLION)
TABLE 126. BRAZIL BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY GLIOMA, 2018-2030 (USD MILLION)
TABLE 127. BRAZIL BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY PITUITARY TUMOR, 2018-2030 (USD MILLION)
TABLE 128. ARGENTINA BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 129. ARGENTINA BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY CHEMOTHERAPY, 2018-2030 (USD MILLION)
TABLE 130. ARGENTINA BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY IMMUNOTHERAPY, 2018-2030 (USD MILLION)
TABLE 131. ARGENTINA BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY RADIOTHERAPY, 2018-2030 (USD MILLION)
TABLE 132. ARGENTINA BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
TABLE 133. ARGENTINA BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY DIAGNOSIS TYPE, 2018-2030 (USD MILLION)
TABLE 134. ARGENTINA BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY BIOPSY, 2018-2030 (USD MILLION)
TABLE 135. ARGENTINA BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY IMAGING, 2018-2030 (USD MILLION)
TABLE 136. ARGENTINA BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2030 (USD MILLION)
TABLE 137. ARGENTINA BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 138. ARGENTINA BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY TUMOR TYPE, 2018-2030 (USD MILLION)
TABLE 139. ARGENTINA BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY GLIOMA, 2018-2030 (USD MILLION)
TABLE 140. ARGENTINA BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY PITUITARY TUMOR, 2018-2030 (USD MILLION)
TABLE 141. EUROPE, MIDDLE EAST & AFRICA BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 142. EUROPE, MIDDLE EAST & AFRICA BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY CHEMOTHERAPY, 2018-2030 (USD MILLION)
TABLE 143. EUROPE, MIDDLE EAST & AFRICA BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY IMMUNOTHERAPY, 2018-2030 (USD MILLION)
TABLE 144. EUROPE, MIDDLE EAST & AFRICA BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY RADIOTHERAPY, 2018-2030 (USD MILLION)
TABLE 145. EUROPE, MIDDLE EAST & AFRICA BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
TABLE 146. EUROPE, MIDDLE EAST & AFRICA BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY DIAGNOSIS TYPE, 2018-2030 (USD MILLION)
TABLE 147. EUROPE, MIDDLE EAST & AFRICA BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY BIOPSY, 2018-2030 (USD MILLION)
TABLE 148. EUROPE, MIDDLE EAST & AFRICA BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY IMAGING, 2018-2030 (USD MILLION)
TABLE 149. EUROPE, MIDDLE EAST & AFRICA BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2030 (USD MILLION)
TABLE 150. EUROPE, MIDDLE EAST & AFRICA BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 151. EUROPE, MIDDLE EAST & AFRICA BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY TUMOR TYPE, 2018-2030 (USD MILLION)
TABLE 152. EUROPE, MIDDLE EAST & AFRICA BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY GLIOMA, 2018-2030 (USD MILLION)
TABLE 153. EUROPE, MIDDLE EAST & AFRICA BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY PITUITARY TUMOR, 2018-2030 (USD MILLION)
TABLE 154. EUROPE, MIDDLE EAST & AFRICA BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 155. UNITED KINGDOM BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 156. UNITED KINGDOM BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY CHEMOTHERAPY, 2018-2030 (USD MILLION)
TABLE 157. UNITED KINGDOM BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY IMMUNOTHERAPY, 2018-2030 (USD MILLION)
TABLE 158. UNITED KINGDOM BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY RADIOTHERAPY, 2018-2030 (USD MILLION)
TABLE 159. UNITED KINGDOM BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
TABLE 160. UNITED KINGDOM BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY DIAGNOSIS TYPE, 2018-2030 (USD MILLION)
TABLE 161. UNITED KINGDOM BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY BIOPSY, 2018-2030 (USD MILLION)
TABLE 162. UNITED KINGDOM BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY IMAGING, 2018-2030 (USD MILLION)
TABLE 163. UNITED KINGDOM BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2030 (USD MILLION)
TABLE 164. UNITED KINGDOM BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 165. UNITED KINGDOM BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY TUMOR TYPE, 2018-2030 (USD MILLION)
TABLE 166. UNITED KINGDOM BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY GLIOMA, 2018-2030 (USD MILLION)
TABLE 167. UNITED KINGDOM BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY PITUITARY TUMOR, 2018-2030 (USD MILLION)
TABLE 168. GERMANY BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 169. GERMANY BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY CHEMOTHERAPY, 2018-2030 (USD MILLION)
TABLE 170. GERMANY BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY IMMUNOTHERAPY, 2018-2030 (USD MILLION)
TABLE 171. GERMANY BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY RADIOTHERAPY, 2018-2030 (USD MILLION)
TABLE 172. GERMANY BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
TABLE 173. GERMANY BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY DIAGNOSIS TYPE, 2018-2030 (USD MILLION)
TABLE 174. GERMANY BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY BIOPSY, 2018-2030 (USD MILLION)
TABLE 175. GERMANY BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY IMAGING, 2018-2030 (USD MILLION)
TABLE 176. GERMANY BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2030 (USD MILLION)
TABLE 177. GERMANY BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 178. GERMANY BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY TUMOR TYPE, 2018-2030 (USD MILLION)
TABLE 179. GERMANY BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY GLIOMA, 2018-2030 (USD MILLION)
TABLE 180. GERMANY BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY PITUITARY TUMOR, 2018-2030 (USD MILLION)
TABLE 181. FRANCE BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 182. FRANCE BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY CHEMOTHERAPY, 2018-2030 (USD MILLION)
TABLE 183. FRANCE BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY IMMUNOTHERAPY, 2018-2030 (USD MILLION)
TABLE 184. FRANCE BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY RADIOTHERAPY, 2018-2030 (USD MILLION)
TABLE 185. FRANCE BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
TABLE 186. FRANCE BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY DIAGNOSIS TYPE, 2018-2030 (USD MILLION)
TABLE 187. FRANCE BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY BIOPSY, 2018-2030 (USD MILLION)
TABLE 188. FRANCE BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY IMAGING, 2018-2030 (USD MILLION)
TABLE 189. FRANCE BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2030 (USD MILLION)
TABLE 190. FRANCE BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 191. FRANCE BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY TUMOR TYPE, 2018-2030 (USD MILLION)
TABLE 192. FRANCE BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY GLIOMA, 2018-2030 (USD MILLION)
TABLE 193. FRANCE BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY PITUITARY TUMOR, 2018-2030 (USD MILLION)
TABLE 194. RUSSIA BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 195. RUSSIA BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY CHEMOTHERAPY, 2018-2030 (USD MILLION)
TABLE 196. RUSSIA BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY IMMUNOTHERAPY, 2018-2030 (USD MILLION)
TABLE 197. RUSSIA BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY RADIOTHERAPY, 2018-2030 (USD MILLION)
TABLE 198. RUSSIA BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
TABLE 199. RUSSIA BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY DIAGNOSIS TYPE, 2018-2030 (USD MILLION)
TABLE 200. RUSSIA BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY BIOPSY, 2018-2030 (USD MILLION)
TABLE 201. RUSSIA BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY IMAGING, 2018-2030 (USD MILLION)
TABLE 202. RUSSIA BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2030 (USD MILLION)
TABLE 203. RUSSIA BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 204. RUSSIA BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY TUMOR TYPE, 2018-2030 (USD MILLION)
TABLE 205. RUSSIA BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY GLIOMA, 2018-2030 (USD MILLION)
TABLE 206. RUSSIA BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY PITUITARY TUMOR, 2018-2030 (USD MILLION)
TABLE 207. ITALY BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 208. ITALY BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY CHEMOTHERAPY, 2018-2030 (USD MILLION)
TABLE 209. ITALY BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY IMMUNOTHERAPY, 2018-2030 (USD MILLION)
TABLE 210. ITALY BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY RADIOTHERAPY, 2018-2030 (USD MILLION)
TABLE 211. ITALY BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
TABLE 212. ITALY BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY DIAGNOSIS TYPE, 2018-2030 (USD MILLION)
TABLE 213. ITALY BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY BIOPSY, 2018-2030 (USD MILLION)
TABLE 214. ITALY BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY IMAGING, 2018-2030 (USD MILLION)
TABLE 215. ITALY BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2030 (USD MILLION)
TABLE 216. ITALY BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 217. ITALY BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY TUMOR TYPE, 2018-2030 (USD MILLION)
TABLE 218. ITALY BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY GLIOMA, 2018-2030 (USD MILLION)
TABLE 219. ITALY BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY PITUITARY TUMOR, 2018-2030 (USD MILLION)
TABLE 220. SPAIN BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 221. SPAIN BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY CHEMOTHERAPY, 2018-2030 (USD MILLION)
TABLE 222. SPAIN BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY IMMUNOTHERAPY, 2018-2030 (USD MILLION)
TABLE 223. SPAIN BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY RADIOTHERAPY, 2018-2030 (USD MILLION)
TABLE 224. SPAIN BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
TABLE 225. SPAIN BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY DIAGNOSIS TYPE, 2018-2030 (USD MILLION)
TABLE 226. SPAIN BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY BIOPSY, 2018-2030 (USD MILLION)
TABLE 227. SPAIN BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY IMAGING, 2018-2030 (USD MILLION)
TABLE 228. SPAIN BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2030 (USD MILLION)
TABLE 229. SPAIN BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 230. SPAIN BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY TUMOR TYPE, 2018-2030 (USD MILLION)
TABLE 231. SPAIN BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY GLIOMA, 2018-2030 (USD MILLION)
TABLE 232. SPAIN BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY PITUITARY TUMOR, 2018-2030 (USD MILLION)
TABLE 233. UNITED ARAB EMIRATES BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 234. UNITED ARAB EMIRATES BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY CHEMOTHERAPY, 2018-2030 (USD MILLION)
TABLE 235. UNITED ARAB EMIRATES BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY IMMUNOTHERAPY, 2018-2030 (USD MILLION)
TABLE 236. UNITED ARAB EMIRATES BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY RADIOTHERAPY, 2018-2030 (USD MILLION)
TABLE 237. UNITED ARAB EMIRATES BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
TABLE 238. UNITED ARAB EMIRATES BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY DIAGNOSIS TYPE, 2018-2030 (USD MILLION)
TABLE 239. UNITED ARAB EMIRATES BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY BIOPSY, 2018-2030 (USD MILLION)
TABLE 240. UNITED ARAB EMIRATES BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY IMAGING, 2018-2030 (USD MILLION)
TABLE 241. UNITED ARAB EMIRATES BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2030 (USD MILLION)
TABLE 242. UNITED ARAB EMIRATES BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 243. UNITED ARAB EMIRATES BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY TUMOR TYPE, 2018-2030 (USD MILLION)
TABLE 244. UNITED ARAB EMIRATES BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY GLIOMA, 2018-2030 (USD MILLION)
TABLE 245. UNITED ARAB EMIRATES BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY PITUITARY TUMOR, 2018-2030 (USD MILLION)
TABLE 246. SAUDI ARABIA BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 247. SAUDI ARABIA BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY CHEMOTHERAPY, 2018-2030 (USD MILLION)
TABLE 248. SAUDI ARABIA BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY IMMUNOTHERAPY, 2018-2030 (USD MILLION)
TABLE 249. SAUDI ARABIA BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY RADIOTHERAPY, 2018-2030 (USD MILLION)
TABLE 250. SAUDI ARABIA BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
TABLE 251. SAUDI ARABIA BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY DIAGNOSIS TYPE, 2018-2030 (USD MILLION)
TABLE 252. SAUDI ARABIA BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY BIOPSY, 2018-2030 (USD MILLION)
TABLE 253. SAUDI ARABIA BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY IMAGING, 2018-2030 (USD MILLION)
TABLE 254. SAUDI ARABIA BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2030 (USD MILLION)
TABLE 255. SAUDI ARABIA BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 256. SAUDI ARABIA BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY TUMOR TYPE, 2018-2030 (USD MILLION)
TABLE 257. SAUDI ARABIA BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY GLIOMA, 2018-2030 (USD MILLION)
TABLE 258. SAUDI ARABIA BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY PITUITARY TUMOR, 2018-2030 (USD MILLION)
TABLE 259. SOUTH AFRICA BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 260. SOUTH AFRICA BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY CHEMOTHERAPY, 2018-2030 (USD MILLION)
TABLE 261. SOUTH AFRICA BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY IMMUNOTHERAPY, 2018-2030 (USD MILLION)
TABLE 262. SOUTH AFRICA BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY RADIOTHERAPY, 2018-2030 (USD MILLION)
TABLE 263. SOUTH AFRICA BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
TABLE 264. SOUTH AFRICA BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY DIAGNOSIS TYPE, 2018-2030 (USD MILLION)
TABLE 265. SOUTH AFRICA BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY BIOPSY, 2018-2030 (USD MILLION)
TABLE 266. SOUTH AFRICA BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY IMAGING, 2018-2030 (USD MILLION)
TABLE 267. SOUTH AFRICA BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2030 (USD MILLION)
TABLE 268. SOUTH AFRICA BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 269. SOUTH AFRICA BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY TUMOR TYPE, 2018-2030 (USD MILLION)
TABLE 270. SOUTH AFRICA BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY GLIOMA, 2018-2030 (USD MILLION)
TABLE 271. SOUTH AFRICA BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY PITUITARY TUMOR, 2018-2030 (USD MILLION)
TABLE 272. DENMARK BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 273. DENMARK BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY CHEMOTHERAPY, 2018-2030 (USD MILLION)
TABLE 274. DENMARK BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY IMMUNOTHERAPY, 2018-2030 (USD MILLION)
TABLE 275. DENMARK BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY RADIOTHERAPY, 2018-2030 (USD MILLION)
TABLE 276. DENMARK BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
TABLE 277. DENMARK BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY DIAGNOSIS TYPE, 2018-2030 (USD MILLION)
TABLE 278. DENMARK BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY BIOPSY, 2018-2030 (USD MILLION)
TABLE 279. DENMARK BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY IMAGING, 2018-2030 (USD MILLION)
TABLE 280. DENMARK BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2030 (USD MILLION)
TABLE 281. DENMARK BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 282. DENMARK BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY TUMOR TYPE, 2018-2030 (USD MILLION)
TABLE 283. DENMARK BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY GLIOMA, 2018-2030 (USD MILLION)
TABLE 284. DENMARK BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY PITUITARY TUMOR, 2018-2030 (USD MILLION)
TABLE 285. NETHERLANDS BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 286. NETHERLANDS BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY CHEMOTHERAPY, 2018-2030 (USD MILLION)
TABLE 287. NETHERLANDS BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY IMMUNOTHERAPY, 2018-2030 (USD MILLION)
TABLE 288. NETHERLANDS BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY RADIOTHERAPY, 2018-2030 (USD MILLION)
TABLE 289. NETHERLANDS BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
TABLE 290. NETHERLANDS BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY DIAGNOSIS TYPE, 2018-2030 (USD MILLION)
TABLE 291. NETHERLANDS BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY BIOPSY, 2018-2030 (USD MILLION)
TABLE 292. NETHERLANDS BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY IMAGING, 2018-2030 (USD MILLION)
TABLE 293. NETHERLANDS BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2030 (USD MILLION)
TABLE 294. NETHERLANDS BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 295. NETHERLANDS BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY TUMOR TYPE, 2018-2030 (USD MILLION)
TABLE 296. NETHERLANDS BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET SIZE, BY GLIOMA, 2018-2030 (USD MILLION)
TABLE 297. NETHERLANDS BRAIN TUMOR DIAGNOSIS & TREATMENT MARKET

Companies Mentioned

The companies profiled in this Brain Tumor Diagnosis & Treatment market report include:
  • Siemens Healthineers AG
  • GE Healthcare LLC
  • Koninklijke Philips N.V.
  • Elekta AB
  • Varian Medical Systems, Inc.
  • Accuray Incorporated
  • Roche Holding AG
  • Novartis AG
  • Merck & Co., Inc.
  • Novocure Limited

Methodology

Loading
LOADING...

Table Information

Report AttributeDetails
No. of Pages181
PublishedMay 2025
Forecast Period2025 - 2030
Estimated Market Value ( USD ) in 2025 $ 1.93 Billion
Forecasted Market Value ( USD ) by 2030 $ 2.69 Billion
Compound Annual Growth Rate6.8%
Regions CoveredGlobal
No. of Companies Mentioned11

Related Topics

Related Reports

Brain Tumor Diagnosis & Therapeutics Market by Therapeutic Modality, Imaging Technology, End User, Tumor Type, Tumor Grade, Patient Age Group - Global Forecast to 2030 - Product Image

Brain Tumor Diagnosis & Therapeutics Market by Therapeutic Modality, Imaging Technology, End User, Tumor Type, Tumor Grade, Patient Age Group - Global Forecast to 2030

  • Report
  • 184 Pages
  • Global
From
Brain Tumor Diagnosis and Therapeutics Market Size, Share & Trends Analysis Report by Type (Primary, Secondary), Product, Diagnosis (MRI, CT, PET-CT), Therapeutics, End Use, and Region with Growth Forecasts, 2025-2030 - Product Image

Brain Tumor Diagnosis and Therapeutics Market Size, Share & Trends Analysis Report by Type (Primary, Secondary), Product, Diagnosis (MRI, CT, PET-CT), Therapeutics, End Use, and Region with Growth Forecasts, 2025-2030

  • Report
  • 100 Pages
  • Global
From
Brain Tumor Diagnosis and Treatment - Global Strategic Business Report - Product Image

Brain Tumor Diagnosis and Treatment - Global Strategic Business Report

  • Report
  • 173 Pages
  • Global
From
Brain Tumor Therapeutics Market by Therapeutic Approach, Product Type, Tumor Type, End User, Distribution Channel - Global Forecast to 2030 - Product Image

Brain Tumor Therapeutics Market by Therapeutic Approach, Product Type, Tumor Type, End User, Distribution Channel - Global Forecast to 2030

  • Report
  • 185 Pages
  • Global
From
Brain Tumor Drug Market Report: Trends, Forecast and Competitive Analysis to 2030 - Product Image

Brain Tumor Drug Market Report: Trends, Forecast and Competitive Analysis to 2030

  • Report
  • Global
From
Copyright © 2002-2025 Research and Markets. All Rights Reserved.